Montana Promotes Right to Try Framework in India
Governor Greg Gianforte introduces a pathway for Indian biotech firms to access clinical data within the United States.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Should states allow patients to access experimental treatments before they receive full federal regulatory approval?
Montana Governor Greg Gianforte traveled to Bengaluru to present the Montana Right to Try framework to Indian biopharma companies. This model offers an alternative route for these firms to access the U.S. market for clinical development.
Why it matters
The framework provides a unique pathway for companies to gather real-world clinical data and generate revenue while pursuing broader regulatory approvals. It effectively invites international developers to leverage the Montana ecosystem for their early-stage research.
The framework requires that experimental treatments meet Phase I safety data standards before being considered. Patient access is contingent on a mandatory review by an independent board of 5 medical professionals.
The players
Greg Gianforte
He is the Governor of Montana who is actively promoting state regulatory frameworks to international biotechnology firms.
Montana Bioscience Alliance
This organization supports the local biotechnology sector by facilitating research navigation and ecosystem integration for new companies.
The details
Under this system, patients travel to Montana to receive treatments at participating clinics, allowing manufacturers to collect clinical data. The Montana Bioscience Alliance assists companies by facilitating navigation of the local biotechnology ecosystem.
Timeline
October 7, 2026: Governor Greg Gianforte visited Bengaluru for a roundtable discussion.
The Tech Race
This initiative marks a departure from standard clinical trial models by integrating the U.S. Right to Try Act into a globalized research recruitment strategy. It positions the Montana ecosystem as a strategic gateway for international firms aiming to compete against established U.S. biotech hubs.
The framework may accelerate the availability of new experimental treatments for patients who travel to participating Montana clinics. For researchers, it offers a functional pathway to navigate complex U.S. clinical requirements more efficiently than traditional regulatory routes.
The takeaway
This international outreach demonstrates how state-level regulatory frameworks are increasingly used as tools for economic and scientific diplomacy. Companies exploring this route should focus on ensuring their experimental products meet the initial Phase I safety data benchmarks required for board approval.
Further reading
For more information on current industry developments, visit the Biotech section.
Source note: This article includes information reported by Biospectrumindia.
Live Poll
Should states allow patients to access experimental treatments before they receive full federal regulatory approval?
